Article info
Letter
Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?
- Correspondence to Dr Anna Merlotti, Department of Radiation Oncology, S Croce and Carle Cuneo Hospital Districts, 12100 Cuneo, Italy; anna.merlotti{at}virgilio.it
Citation
Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?
Publication history
- Accepted April 5, 2021
- First published April 28, 2021.
Article Versions
- You are currently viewing a Previous version of this article (28 April 2021).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.